semaj83/ctmatch_classification huggingface dataset:
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 10.0-14.0,  Turner's Syndrome ENTRY Turner's syndrome-compatible karyotype No Y material in peripheral karyotype Bone age no greater than 11 years --Prior/Concurrent Therapy- No more than 12 months of prior estrogen, androgen, or growth hormone
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 10.0-60.0,  Growth Hormone Deficiency Familial Dwarfism of Sindh Severe short stature but proportionate without dysmorphic features Normal body size and weight at birth Bone age is severely delayed Puberty is somewhat delayed (age 15-16) Fertility present in at least 3 dwarfs
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Growth Disorders Short stature and/or constitutional growth delay No epilepsy or risk of epilepsy
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 5.0-12.0,  Cystic Fibrosis CF patients ages 5-12 who are less than the 25th percentile for age and sex normal values for height and/or weight
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Turner's Syndrome for TS Subjects: Phenotypic females greater than or equal to 10 years of age Evidence of X-chromosomal abnormality Those with a karyotype of 45X/46XX must have at least 80% 45X lymphocytes  for TS Subjects: Co-existing autosomal defects Pregnancy for the Parents of TS Subjects (for DNA only): Biological parent of a TS subject Willingness to participate for the Parents of TS Subjects (for DNA only): None
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Osteoporosis Turner's Syndrome Girls and women with TS diagnosed by karyotype or other genetic evidence of X-chromosome defects and ovarian failure (diagnosed by failure to enter puberty spontaneously by age 18 or 2nd degree amenorrhea greater than 6 months and FSH greater than 40 mIU/ml) Subjects with TS who have been previously exposed to estrogen and progestin effect, either endogenous or exogenous by medical treatment, sufficient to establish secondary sexual development and menses Subjects with TS ages 14 to 50, who have completed near final height, as demonstrated by a bone age of greater than or equal to 14 years  Chronological or bone age of less than 14 years Chronological age greater than 50 years Chromosomal disorders in addition to TS Absence of 2nd degree sexual development Growth hormone or androgen treatment within 6 months of starting study. Testosterone level greater than normal range for age. Contraindications to the use of estrogen, progestin or androgens: Neoplasia; Hypercoagulation disorder; Pregnancy; Gall bladder, biliary or liver parenchymal disease (evidenced by jaundice, gastrointestinal symptomatology, other clinical evidence of cholelithiasis or hepatitis); Hypertriglyceridemia (TGs greater than 300); Active coronary disease (evidenced by documented MI or coronary angiography. Mental or physical disability, which in the estimation of study investigators, prevents a candidate from participation in study
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Usher Syndrome Retinitis Pigmentosa Congenital Hearing Impairment Any Ashkenazi Jewish individual with combined hearing and visual loss that is or may be any type of Usher syndrome, or a family member of said individual  Any individual who is not an Ashkenazi Jew or does not have combined hearing and visual loss or whose disease has been previously determined not to be Usher syndrome
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  HIV Infections HIV positive to 24 weeks pregnant Willing to take the planned antibiotic treatment Planning to deliver at 1 of the study sites Willing to come back for follow-up visits for 1 year after the baby is born  Have taken antibiotics, except for syphilis or gonorrhea, within the last 2 weeks Are allergic to penicillin, ampicillin, erythromycin, or metronidazole Have major illnesses, such as diabetes, severe kidney or heart disease, or active tuberculosis, which might affect the pregnancy Are having major problems with the pregnancy, such as placenta previa, ruptured membranes, or multiple pregnancy Have a central nervous system disease, such as seizures Are taking anticoagulant drugs
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Genetic Disorder Metabolic Disease Patients with suspected or diagnosed genetic and/or metabolic conditions of all ages are eligible for this protocol In addition, children with unexplained developmental delay, deafness, dysmorphism, congenital malformations, acidosis, failure to thrive, feeding problems, short stature, birth defects, and other syndromes of sporadic or unknown etiology will qualify for this protocol The actual selection of patients most appropriate for research and clinical training needs will be made by protocol investigators  Patients that their care requires resources not available at the NIH Clinical Center will not be eligible for the in-patient part of this study There are no exclusions for the out-patient or DNA collection part of the study
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 10.0-14.0,  Turner Syndrome Karyotype diagnosis compatible with Turner syndrome, but no presence of any Y material in the peripheral karyotype unless a gonadectomy has been performed Chronological age between 10.0 and 14.9 years Bone age less than or equal to 12 years; and No treatment with estrogen, androgen, growth hormone, or any other growth-promoting agents exceeding 12 months, and no treatment with any of these agents in the previous 3 months
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 2.0-999.0,  Healthy Pituitary Disease Thyroid Disease STUDY -All adults and children requiring dynamic testing of the hypothalamic-pituitary axis for the evaluation of pituitary reserve, inconsistent thyroid function test, inappropriate TSH secretion, or pre-and post-operative evaluation of pituitary adenomas (glycoprotein hormone secreting tumors, growth hormone secreting tumors and TSH secreting tumors)  Uncontrolled hypertension Uncontrolled seizure disorder Unstable coronary disease Known allergy to TRH. -TRH is available for use in other IRB approved research protocols either using the standard diagnostic testing protocol or the modified TRH test Untreated hypertension Coronary artery disease History of asthma History of seizures Pregnancy Known allergy to TRH
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 6.0-60.0,  Mental Retardation Developmental Delay Disorder Primary diagnosis of mental retardation (IQ < 70) Scheduled for medication reductions from psychotropic drugs and subsequent placement on risperidone Severe self-injury, aggression, property destruction, or stereotypic behavior for 6 months prior to study entry No seizures, or seizures under control of medication for previous 2 years Additional for Substudy Participants in the primary study who are available for 2 hour weekly or bi-weekly clinic visits and are able to have observers in their home, school, and/or work environment  Degenerative disease that may affect motor or cognitive functioning Progressive disease of an organ system Advanced age that may produce deteriorating cognitive or motor functioning Multiple sensory or motor disabilities that will interfere with seeing the stimuli and responding to the computer
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-30.0,  Neuroblastoma Histologically or cytologically confirmed neuroblastoma or ganglioneuroblastoma meeting 1 of the following staging Newly diagnosed disease, at least 1 year of age, and meets for 1 of the following International Neuroblastoma Staging System (INSS) stage 2a/2b with MYCN amplification (greater than 10) AND unfavorable pathology INSS stage 3 with MYCN amplification OR unfavorable pathology Newly diagnosed INSS stage 4 disease meeting for 1 of the following Over 18 months of age Age 12 to 18 months with any unfavorable biologic feature (MYCN amplification, unfavorable pathology, and/or DNA index=1) or any biologic feature that is indeterminant, unsatisfactory, or unknown No INSS stage 4 disease and age 12 to 18 months with all 3 favorable biologic features (i.e., nonamplified MYCN, favorable pathology, and DNA index greater than 1) Newly diagnosed INSS stage 3, 4, or 4S disease AND under 1 year of age with MYCN amplification At least 1 year of age and initially diagnosed with INSS stage 1, 2, or 4S disease that progressed to stage 4 without interval chemotherapy
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 12.0-18.0,  Anorexia Nervosa Females Only with Anorexia Nervosa and Amenorrhea 12-18 years Normal-weight girls 12-18 years with no past or present history of an eating disorder  Diseases affecting bone metabolism (including untreated thyroid disease, premature ovarian failure, diabetes, cancer, pituitary, renal disease or bone fracture within the past six months) Use of prescription medications affecting bone metabolism within three months Suicidality Psychosis Substance abuse Hematocrit <30 % Potassium <3.0 mmol/L Glucose <50 mg/dl
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 12.0-17.0,  Dwarfism, Pituitary Adolescent boys who are GH deficient and Tanner Stage 2 or greater (testes 3 mL or greater) Adolescent girls who are GH deficient and breast Tanner Stage 2 or greater Current treatment with GH dose of 0.4 to 0.7 mg/kg/wk Ability to keep follow-up appointments throughout the study Willingness to remain on therapy until epiphyseal closure is achieved Prior enrollment in NCGS Core Study 85-036  Treatment with non-Genentech GH preparation Closed epiphyses Active neoplasia Treatment with insulin for diabetes
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-17.0,  Dwarfism, Pituitary Turner Syndrome Bone age of at least 15 years for girls or at least 16 years for boys within 6 months of obtaining the DXA scan Previous enrollment in the NCGS core study, 85-036 Tanner Stage 4 or greater Either spontaneous or induced puberty Subjects who plan on terminating GH treatment for statural purposes for one or more of the following reasons: epiphyseal fusion, slowing growth rate indicates that near adult height has been reached, or satisfied with current height  Current therapy with a non Genentech GH product Pregnancy (to avoid exposure to low levels of radiation from DXA scanners) Bilateral hip replacement Weight >130 kg (286 lb.)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-17.0,  Turner Syndrome Are girls with Turner syndrome who are being or will be treated with Nutropin, Nutropin AQ, or Protropin Are willing to keep follow-up appointments throughout study participation Are girls with Turner syndrome who have submitted Form 4 upon discontinuation and may also submit Form 9  Have Noonan syndrome Subjects treated within the last 6 months with a non-Genentech GH preparation Have closed epiphyses prior to NCGS enrollment Have active neoplasia
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Clear Cell Renal Cell Carcinoma Recurrent Renal Cell Cancer Stage III Renal Cell Cancer Stage IV Renal Cell Cancer Patients must have histologically or cytologically confirmed renal cell carcinoma which is either metastatic (M1) or unresectable (M0); patients must have a component of conventional clear cell renal carcinoma; patients with true papillary renal cell carcinoma, sarcomatoid features without any clear cell component, chromophobe, oncocytoma, collecting duct tumors and transitional cell carcinoma are NOT eligible Patients must have measurable disease; soft tissue disease, which has been radiated in the 2 months prior to registration, is not assessable as measurable disease; X-rays, scans, or physical examinations used for tumor measurement must have been completed within 28 days prior to registration; X-rays, scans or physical examinations for non-measureable disease must have been completed within 42 days prior to registration; all disease must be assessed Patients with metastatic disease who have a resectable primary tumor and are deemed a surgical candidate may have undergone resection and have recovered from surgery; at least 28 days must have elapsed since surgery and patient must have recovered from any adverse effects of surgery Patients must not have received any prior systemic therapy for renal cell carcinoma, including chemotherapy, interferon, interleukin-2, other biologic response modifiers, anti-angiogenic therapy, hormonal therapy, or any other experimental systemic therapy; prior treatment with thyroid medications is allowed Patients may have received prior radiation therapy to less than 25% of the bone marrow; at least 28 days must have elapsed since completion of prior radiation therapy; patients must have recovered from all associated toxicities at the time of registration Total bilirubin =< institutional upper limit of normal SGOT or SGPT =< 2.5 x institutional upper limit of normal Serum creatinine =< institutional upper limit of normal or calculated creatinine clearance >= 60 mL/min for patients with creatinine levels above institutional normal Patients who have had a prior nephrectomy must have a serum creatinine =< 2 x institutional upper limit of normal Patients must be offered the opportunity to consent for specimen submission